40. Shi J, Son MY, Yamada S, Szabova L, Kahan S, et al. (2008) Membrane-type MMPs enable extracellular matrix permissiveness and mesenchymal cell proliferation during embryogenesis. Dev Biol 313(1): 196–209. 41. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, et al. (2001) Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J Biol Chem 276(22): 18786–18794. 42. Tochowicz A, Goettig P, Evans R, Visse R, Shitomi Y, et al. (2011) The dimer interface of the membrane type 1 matrix metalloproteinase hemopexin domain: Crystal structure and biological functions. J Biol Chem 286(9): 7587–7600. 43. Itoh Y, Seiki M (2006) MT1-MMP: A potent modifier of pericellular microenvironment. J Cell Physiol 206(1): 1–8. 44. Vuoriluoto K, Hognas G, Meller P, Lehti K, Ivaska J (2011) Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through alpha2beta1 integrin and MT1-MMP. Matrix Biol 30(3): 207–217. 45. Bardos H, Molnar P, Csecsei G, Adany R (1996) Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis 7(5): 536–548. 46. Costantini V, Zacharski LR (1992) The role of fibrin in tumor metastasis. Cancer Metastasis Rev 11(3–4): 283–290. 47. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: A cancer microarray database and integrated data-mining platform. Neoplasia 6(1): 1–6. 48. Casley-Smith JR, Florey HW (1961) The structure of normal small lymphatics. Q J Exp Physiol Cogn Med Sci 46: 101–106. 49. Pflicke H, Sixt M (2009) Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med 206(13): 2925–2935. 50. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, et al. (2000) Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 96(10): 3302–3309. MT3-MMP in Matrix-Dependent Melanoma Invasion 51. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, et al. (2002) Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 62(23): 6966–6972. 52. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, et al. (2009) Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11(11): 1287–1296. 53. Ferraro GB, Morrison CJ, Overall CM, Strittmatter SM, Fournier AE (2011) Membrane-type matrix metalloproteinase-3 regulates neuronal responsiveness to myelin through nogo-66 receptor 1 cleavage. J Biol Chem 286(36): 31418–31424. 54. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, et al. (1985) Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45(11 Pt 2): 5670–5676. 55. MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS (1999) ‘Proteolytic switching’: Opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 80(3–4): 504–512. 56. Illman SA, Lehti K, Keski-Oja J, Lohi J (2006) Epilysin (MMP-28) induces TGF- beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 119(Pt 18): 3856–3865. 57. Tatti O, Vehvilainen P, Lehti K, Keski-Oja J (2008) MT1-MMP releases latent TGF-beta1 from endothelial cell extracellular matrix via proteolytic processing of LTBP-1. Exp Cell Res 314(13): 2501–2514. 58. Lehti K, Valtanen H, Wickstrom SA, Lohi J, Keski-Oja J (2000) Regulation of membrane-type-1 matrix metalloproteinase activity by its cytoplasmic domain. J Biol Chem 275(20): 15006–15013. PLoS ONE | www.plosone.org 13 December 2011 | Volume 6 | Issue 12 | e28325